Table 3.
Overview of clinical trials for investigation of cannabinoids in cancer. Key search terms included: “Cancer and Cannabinoids, Cannabis, Cannabidiol, Tetrahydrocannabinol” (www.clinicaltrials.gov)
| Trial name | Conditions | Phase | n | Study type | Drug | Location | Status | NCT no. |
|---|---|---|---|---|---|---|---|---|
| A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas | Brain Neoplasms|Nausea|Vomiting | I | 33 | Interventional | Dronabinol | North Carlina, USA | Completed | NCT00314808 |
| A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours | Solid Tumour | I | 40 | Interventional | Dexanabinol|Other: Cremophor | Leeds/Newcastle/Glasgow | Completed | NCT01489826 |
| A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma | Cancer | I/II | 6 | Interventional | Sativex | Leeds/Bristol/London | Completed | NCT01812603 |
| A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients | Cancer | I/II | 21 | Interventional | Sativex|Placebo | Germany | Completed | NCT01812616 |
| A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis | Head and Neck Squamous Cell Carcinoma | I | 10 | Interventional | Sativex | London | Terminated | NCT01975688 |
| Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects | Safety|Tolerability|Pharmacokinetics|Cancer | I | 40 | Interventional | Dexanabinol, Placebo | Nottingham | Completed | NCT02054754 |
| A Study: Pure CBD as Single-agent for Solid Tumor | Solid Tumor | II | 60 | Interventional | Cannabidiol | Israel | Unknown status | NCT02255292 |
| A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Hepatocellular Carcinoma|Pancreatic Cancer | I | 112 | Interventional | Dexanabinol| Sorafenib| Nab-paclitaxel| Gemcitabine | Switzerland/Germany/Spain | Unknown status | NCT02423239 |
| A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer | Advanced Cancer | I | 0 | Interventional | Sativex | United Kingdom | Withdrawn | NCT02432612 |
| Study on Cannabinoid Receptor Expression in Gastrointestinal Diseases | Ulcerative Colitis|Crohn's Disease|Colon Cancer | – | 31 | Observational | N/A | Austria | Completed | NCT02735941 |
| The Effect of Cannabis in Pancreatic Cancer | Neoplasms Pancreatic|Cachexia; Cancer|Cannabis|Appetite Loss|Palliative Medicine|Morbidity|Mortality | II | 32 | Interventional | THC and CBD Mixture | Denmark | Unknown status | NCT03245658 |
| Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma | Glioblastoma | I | 1 | Interventional | Cannabis| Temozolomide| Radiation Therapy | New York, USA | Terminated | NCT03246113 |
| Medical Cannabis During Chemoradiation for Head and Neck Cancer | Head and Neck Cancer | – | 30 | Observational | Cannabis | New York, USA | Recruiting | NCT03431363 |
| TN-TC11G (THC + CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma | Glioblastoma | I/II | 30 | Interventional | TN-TC11G| Temozolomide Oral Product| Radiotherapy | Spain | Not yet recruiting | NCT03529448 |
| A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | Cancer of Pancreas|Cancer of Liver|Cancer of Rectum|Cancer of Colon|Cancer, Gall Bladder|Myeloma Multiple|Glioblastoma Multiforme | I/ II | 160 | Interventional | Cannabidiol| Bortezomib| Leucovorin| 5-FU| Oxaliplatin| Bevacizumab| Irinotecan| Gemcitabine| Temozolomide | Orlando/Florida, USA | Not yet recruiting | NCT03607643 |
| Cannabis Use in Cancer Patients | Solid Tumor, Adult | – | 30 | Observational | Cannabis | Colorado, USA | Recruiting | NCT03617692 |
| Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets | Bone Metastases|Breast Cancer|Pain | Early I | 20 | Interventional | Syndros | Arizona, USA | Recruiting | NCT03661892 |
| Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products | Cancer and other ailments | – | 10 | Observational | Registry|Other: PK microsampling of blood | Philadelphia/ Pennsylvania, USA | Terminated | NCT03886753 |
| Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer | Pancreatic Cancer Non-resectable|Chemotherapy-induced Nausea and Vomiting|Pancreatic Cancer Metastatic | III | 140 | Interventional | Dronabinol in Oral Dosage Form| Placebo in Oral Dosage Form | Austria | Recruiting | NCT03984214 |
| Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer | Stage IV Prostate Cancer|Stage IV Colon Cancer|Stage IV Breast Cancer|Stage IV Cancer of the Cervix | Early I | 104 | Interventional | Dibenzyl trisulphide capsules| Placebo | Jamaica | Unknown status | NCT04113096 |
| Effect of Hemp-CBD on Patients With CIPN | Chemotherapy-induced Peripheral Neuropathy|Colorectal Cancer Stage II|Colorectal Cancer Stage III|Breast Cancer|Ovarian Cancer|Uterine Cancer | II | 100 | Interventional | Hemp-based CBD| Placebo oral tablet | Pennsylvania, USA | Recruiting | NCT04398446 |
| Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer | Prostate Cancer Recurrent|Prostate Cancer|Prostate Adenocarcinoma | I | 18 | Interventional | Epidiolex Oral Liquid | Kentucky, USA | Recruiting | NCT04428203 |